Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate

Jake G. Besch-Stokes, Meera H. Patel, Caitlin M. Brumfiel, Collin M. Costello, William Rule, Allison Rosenthal, Mark R. Pittelkow, David J. Dicaudo, Aaron R. Mangold

Research output: Contribution to journalArticlepeer-review


Cutaneous B-cell pseudolymphoma (CBPL), or cutaneous lymphoid hyperplasia, is the most common pseudolymphoma. It typically responds well to local treatment and follows a benign course. Herein, we describe the unique case of a patient with CBPL that was refractory to a variety of treatments, with subsequent response to rituximab followed by methotrexate. This case explores the complex interplay of T and B lymphocytes, and the potential role of perifollicular T cells in treatment resistant CBPL Further, it describes the additive therapeutic effect of rituximab and methotrexate to target both B cell and T cell populations in CBPL, a strategy already employed in a number of other conditions.

Original languageEnglish (US)
Article number8
JournalDermatology Online Journal
Issue number9
StatePublished - 2021


  • B-cell disorders
  • Methotrexate
  • Pseudolymphoma
  • Rituximab

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Cutaneous B-cell pseudolymphoma treated with rituximab and methotrexate'. Together they form a unique fingerprint.

Cite this